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VaccineModiﬁed vaccinia Ankara (MVA) is an attenuated vaccinia virus, and is a promising vaccine vector for variola
and monkeypox viruses, as well as for other pathogens. The MVA determinants important for vaccine efﬁcacy
and immunogenicity are poorly deﬁned. MVA infection of ﬁbroblast cells activates NF-κB, a characteristic not
ascribed to wild-type vaccinia viruses. Thus, NF-κB activation, and the subsequent upregulation of host
immune molecules, could be one of the determinants for MVA's immunogenicity. We report that ERK2
phosphorylation, an event preceding and required for NF-κB activation, occurred rapidly after virus infection.
ERK2 and NF-κB remained inert when virus endocytosis was prevented, suggesting that virus–host cell
interactions were insufﬁcient for activating NF-κB. Inhibition of viral protein synthesis decreased NF-κB
activation, and elimination of intermediate and late gene expression did not alter MVA-induced NF-κB
activation. Thus, early gene expression activates NF-κB.© 2009 Elsevier Inc. All rights reserved.Introduction
Nuclear factor-κB (NF-κB) is a conserved eukaryotic transcrip-
tion factor that is important for the immune system; it controls the
expression of cytokines, MHC proteins, apoptotic factors, and cell
adhesion molecules (Hoffmann, Natoli, and Ghosh, 2006). The
canonical pathway triggering NF-κB activation is well-characterized
(Gilmore, 2006). Prior to activation, the p65/p50 heterodimeric
NF-κB complex is inactive in the cytoplasm, bound to its inhibitory
protein, IκBα. Diverse events, such as virus infection, will activate
the I kappa kinase complex (IKK) complex. Once IKK phosphor-
ylates IκBα (DiDonato et al., 1997; Mercurio et al., 1997), IκBα is
degraded (Baldi et al., 1996; Chen et al., 1995). The NF-κB NLS is
then exposed and NF-κB relocates to the nucleus, where the
transcription factor binds to a conserved DNA sequence to regulate
gene expression.
The control of NF-κB activation during a natural virus infection
can have great consequences (Hiscott et al., 2006). NF-κB inhibition,
for example, is detrimental for a host, by virtue of viral proteins
dampening components of the innate and speciﬁc immune
responses. In contrast, virus-induced NF-κB activation may be
beneﬁcial to the host because anti-viral immune responses to
neutralize virus infections are activated. The effect of the virus-
mediated NF-κB activation is well-documented for cells infected
with vaccinia virus, a virus that is highly similar to variola virus andll rights reserved.an effective vaccine against smallpox (Moss, 2007). An attenuated
vaccinia virus, such as the modiﬁed vaccinia Ankara (MVA) strain
(Mayr, Hochstein-Mintzel, and Stickl, 1975), induces NF-κB activa-
tion in host cells, whereas wild-type vaccinia strains do not (Oie
and Pickup, 2001; Shisler and Jin, 2004).
Wild-type vaccinia viruses utilize myriad mechanisms to inhibit
NF-κB activation, including the synthesis of proteins that inhibit
Toll-like-, interleukin-1β receptor- and tumor necrosis factor
receptor-induced signaling (Alcami et al., 1999; Alcami and Smith,
1992; Bowie et al., 2000). However, the molecular mechanism
responsible for MVA-induced NF-κB activation is unknown. The
elucidation of this viral mechanism is important information when
understanding how MVA regulates immune responses in vivo, and
in considering the design of future MVA-based vaccines against
smallpox or other infectious diseases. To this end, the stage of the
MVA lifecycle responsible for activating NF-κB was identiﬁed in the
293T ﬁbroblast cell line. Using molecular and pharmacological
inhibitors, it was found that virus binding to or entry into host
cells was not sufﬁcient to trigger the activation of this cellular
transcription factor, nor did Toll-like receptor signaling appear to
be important for the MVA phenotype. Instead, viral protein
expression was required for the NF-κB nuclear translocation in
the 293T ﬁbroblast cell line. Poxviral gene expression is temporal,
and ORFs are grouped into early, intermediate or late genes, based
on promoter sequences and time of expression during infection
(Moss, 2007). MVA infections under conditions preventing inter-
mediate or late gene expression did not ablate NF-κB or ERK2
activation, suggesting that early gene expression is responsible for
this phenotype.
Fig. 1. Temporal NF-κB nuclear translocation and ERK1/2 phosphorylation during
vaccinia infection. 293T monolayers were either mock-infected or infected with MVA
(MOI=10). At the times indicated post-infection, cells were collected and lysed, and
cytoplasmic and nuclear extracts were isolated. (A) 5 μg of nuclear-extracted proteins
from each sample was incubated with 32P-radiolabeled oligonucleotides containing
consensus NF-κB binding sites, and analyzed via an electromobility shift assay. The
location of the mobility-shifted band containing NF-κB is indicated by an asterisk (⁎).
For some reactions, the nuclear-extracted proteins from MVA-infected cells (4 h post-
infection) were also incubated with excess amount of non-radiolabeled oligonucleo-
tides containing either NF-κB binding sites (NF-κB) or lacking NF-κB binding sites
(AP1), or with anti-NF-κB antibodies recognizing the p65 subunit of the NF-κB dimer
(p65 Ab). The super-shifted band containing anti-p65 is indicated by the “+” symbol.
(B) 20 μg of the cytoplasmically extracted proteins was electrophoretically separated via
SDS-12% PAGE. Proteins were transferred to PVDF membranes, and immunoblots (IBs)
were subsequently probed with antiserum recognizing the phosphorylated forms of
ERK2 and ERK1 (p-ERK1/2) or the unmodiﬁed forms of ERK1 and ERK2 (ERK1/2).
Molecular weight markers (MW) in kDa are indicated on the left-hand side of the
immunoblot. Densitometry analysis was performed to quantify the phospho-ERK2
levels in the immunoblot. The signal from the lane containing lysates from mock-
infected cells was set as a value equal to one. The amount of phospho-ERK2 in lanes
containing lysates from MVA-infected cells was graphically represented as a fold-
increase above that observed for mock-infected cells.
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NF-κB and ERK2 activation occur early during MVA infection, and EKR2
phosphorylation precedes NF-κB activation
It was shown previously that MVA infection of 293T cells results in
host cell NF-κB activation (Oie and Pickup, 2001; Shisler and Jin,
2004). To determine when this event occurred during poxvirus
infection, we detected NF-κB nuclear translocation, a hallmark of NF-
κB activation, in virus-infected cells by using EMSA. When NF-κB is
present in the nuclear extracts, and therefore active, it binds to
radiolabeled oligonucleotides and retards their mobility. While there
weremultiple bands present in all lanes, one unique bandwas present
in the lane containing extracts from infected cells harvested at 2–12 h
post-infection (Fig. 1A). This same band increased in intensity until
4 h post-infection, remained relatively high until 10 h post-infection,
and then decreased in intensity at 12 h post-infection (Fig. 1A). It was
veriﬁed that the unique mobility-shifted band indeed contained the
NF-κB complex: when antibody recognizing the p65 subunit of NF-κB
was present, and presumably binding to NF-κB, the unique band
disappeared and a higher-mobility band appeared. The NF-κB-
containing band disappeared in reactions containing of non-labeled
oligonucleotides possessing NF-κB binding sites, but remained when
non-labeled oligonucleotides instead possessing the AP1 binding site
were present.
Activation of the ERK2 protein is necessary forMVA-inducedNF-κB
nuclear translocation in 293T cells (Gedey et al., 2006). Therefore,
ERK2 phosphorylation should temporally precede MVA-induced NF-
κB activation. To verify this, the presence of the active, phosphorylated
(phospho-) ERK2 was detected at different times post-infection by
using immunoblotting. Indeed, ERK2 activation occurred before NF-κB
activation; a 42 kDa phospho-ERK2 band was detected in cells
harvested as early as 30 min post-infection (Fig. 1B). ERK2 activation,
as measured by the intensity of the phospho-ERK2-containing band,
peaked between 3 and 4 h post-infection, paralleling maximal NF-κB
nuclear translocation in MVA-infected cells. Finally, ERK2 phosphor-
ylationwaned 6 h post-infection, and was no longer detectable 8–12 h
post-infection (Fig. 1B), even though NF-κB was still present in the
nucleus of virus-infected cells at these times (Fig. 1A). The anti-
phospho-ERK2 antibody also cross-reacts with the highly similar
phospho-ERK1 protein, as is evidenced by the presence of a higher
molecular weight, 44 kDa band in most samples (Fig. 1B). The
differences in phosphorylated ERK2 levels were not due to uneven
protein loading since similar amounts of ERK1 and ERK2 proteinswere
detected in each reaction (Fig. 1B). The density of phospho-ERK2-
containing bands was quantiﬁed by using densitometry. Values for
phosph-ERK2-speciﬁc signals were computed by dividing the value of
the signal obtained from lanes containing lysates from virus-infected
cells by the value of the signal obtained from the lane containing
lysates from mock-infected cells. The differences in phospho-ERK2
band intensities were represented graphically, and mimicked the
trends observed in the immunoblot in Fig. 1B. When comparing the
phospho-ERK2 levels, the density of the phospho-ERK2 band the lane
containing lysates from mock-infected cells was set at a value of “1,”
and the value for other treatments (virus infection) was presented as
fold-increases over the value obtained for mock-infected cells. For this
particular immunoblot, the phospho-ERK2 levels in cells at 3 h post-
infection is approximately 9-fold higher than that observed during
mock infection.
MVA does not utilize the MyD88 accessory protein to activate NF-κB
in 293T cells
MVA activation of dendritic cells (DCs) requires, in part, the Toll-
like receptor 9 (TLR9), an intracellular molecule known to trigger
NF-κB activation (Samuelsson et al., 2008). Since NF-κB activation isnecessary for DC activation (Rowe et al., 2008), we queried if the
TLR signal transduction pathway was responsible for MVA-induced
NF-κB activation in 293T cells. To this end, 293T cells ectopically
over-expressing dominant negative mutant MyD88 proteins were
infected with MVA, and NF-κB activation was measured via a
luciferase-based reporter assay, in which a luciferase gene is under
300 S. Martin, J.L. Shisler / Virology 390 (2009) 298–306the transcriptional control of an NF-κB promoter. Results are shown
in Fig. 2. Luciferase activity levels were increased about 7-fold in
lysates from MVA-versus mock-infected cells, inferring that MVA
activated NF-κB. As previously published (Gedey et al., 2006), the
over-expression of a dominant negative ERK2 protein diminished
luciferase activity. In contrast, luciferase activity levels in
pMyD88DN-transfected cells were higher than those observed for
either pERK2DN or untransfected cells, suggesting that MVA-
induced NF-κB activation did not require MyD88-dependent TLR
activation. To conﬁrm that the dominant negative MyD88 protein
was expressed at levels that were biologically signiﬁcant, a separate
set of pMyD88-transfected cells were incubated with interleukin-1β
(IL-1β), a cellular cytokine that utilizes the MyD88 accessory
protein to activate NF-κB. As would be expected, IL-1β-mediated
luciferase activity was greatly diminished in pMyD88DN-transfected
cells versus pcDNA3.1-transfected cells. Notably, MVA-induced
luciferase activity remained unaffected in pMyD88DN-transfected
cells, inferring that the ERK2 activation pathway remained intact in
these cells.
Virus binding to the cell membrane and viral endocytosis is not sufﬁcient
to activate NF-κB
Since NF-κB activation and ERK2 phosphorylation occurred
relatively early during virus infection, one of the following events
was responsible: virus binding to the host cell, virus entry into the cell,
early viral protein expression, or DNA replication. To test if virus
binding to the host cell was sufﬁcient to activate NF-κB, the virus
adsorption stage of infection occurred at 4 °C and in the presence ofFig. 2. MVA-induced NF-κB activation in cells expressing a dominant negative mutant
MyD88 protein. 293Tcellular monolayers were co-transfected with pRL-null, pNF-κBluc
and either pERK2DN or pMyD88DN, as indicated. At 24 h later, cellular monolayers were
either mock-infected or infected with MVA (MOI of 10). An additional set of
pMyD88DN-transfected cells was instead incubated with 10 ng or 20 ng IL-1β per ml
medium for 4 h. At 4 h post-infection cells were harvested, collected by centrifugation
and incubated in passive lysis buffer. Fireﬂy and sea pansy luciferase activities were
measured, and the resultant ratios were normalized to that value obtained using
untreated, uninfected cells.anti-L1R antibodies. Infections then proceeded for 4 h at 37 °C. This
treatment allows virus binding to the host cell, but prevents entry
(Ichihashi, Takahashi, and Oie, 1994; Ramsey-Ewing and Moss, 1998).
Under these conditions, there was a dramatic decrease in MVA-
mediated NF-κB nuclear translocation as compared to MVA-infected
cells incubated in medium lacking antibodies or in medium with
antibodies not speciﬁc to vaccinia virus (Fig. 3A). As would be
expected, NF-κB remained inactive if non-speciﬁc antibodies were
present during mock infection or during infection with WR, a wild-
type strain of vaccinia virus that inhibits host cell NF-κB activation
(Shisler and Jin, 2004). Similar to Fig. 1A, the addition of anti-p65
antibodies to reactions containing extracts from MVA-infected cells
super-shifted the NF-κB-containing band, verifying the presence of
NF-κB in the observed band.
The effectiveness of anti-L1 antibody treatment to prevent virus
entry was measured indirectly, by detecting viral protein synthesis in
lysates from infected cells (Fig. 3B). When probing cytoplasmic
extracts from WR- or MVA-infected cells with polyclonal antiserum
raised against whole vaccinia virions, several unique bands (110 kDa,
35 kDa, 27 kDa, 15 kDa) were present, indicating that the polyclonal
anti-vaccinia virus antiserum recognized multiple vaccinia virus
proteins. In comparison, these bands' intensities were greatly
decreased when assaying lysates from anti-L1, MVA-infected cells
(Fig. 3B), inferring that the anti-L1 treatment indeed impeded virus
entry into cells. Since actin levels were similar in all samples, the
differences in viral protein levels were not due to unequal protein
levels in each reaction.
It was reported recently that vaccinia virus penetration of the host
cell occurs via a dynamin-dependent endocytosis pathway, an event
inhibited by dynasore (Huang et al., 2008). As shown in Fig. 3C, when
virus infections occurred in the presence of dynasore, NF-κB no longer
translocated to the nucleus, indicating that virus binding and
endocytosis was not sufﬁcient for virus-induced NF-κB activation.
Detection of viral E3 protein, an early vaccinia protein expressed only
after viral endocytosis, was utilized as a mechanism to indirectly
conﬁrm the effectiveness of dynasore treatment (Fig. 3D). Indeed, the
intensity of band representing the 20 kDa E3 product was dramatically
decreased when infections proceeded in the presence versus the
absence of dynasore.
It was expected that ERK2 would remain inactive when MVA
infections occurred in the presence of dynasore. As predicted, there
was a decrease in MVA-mediated ERK2 activation in the presence of
dynasore, as measured by detection of phosphorylated ERK2 by
immunoblotting (Fig. 3D). When comparing the intensity of the
phospho-ERK2 bands in this immunoblot by using densitometry, it
was observed that the phospho-ERK2 levels in cells treated with
40 μM dynasore was similar (approximately 1), regardless of
whether cells were infected or mock-infected. While there was a
slight increase in the phospho-ERK2 levels in MVA-versus mock-
infected cells in conditions in which cells were treated with 80 μM
dynasore (1 versus 0.5), levels were still lower than those observed
for MVA infection (approximately 2) in the absence of drug. For this
immunoblot, the fold-increase in phospho-ERK2 levels in MVA-
infected cells was lower than that observed for Fig. 1, and this may
be due to the presence of DMSO. Detection of similar amounts of
ERK1 and ERK2 proteins in each sample negated the possibility that
differences in phospho-ERK2 levels were due to decreased amounts
of proteins in each sample.
Viral protein expression is necessary for MVA-induced NF-κB activation
Cordycepin is a nucleoside adenosine derivative that prevents
the translation of poxviral mRNA (Esteban and Metz, 1973). Thus,
its presence during infection would assess the role of viral
proteins synthesis on MVA-induced NF-κB activation. Since NF-κB
remained inactive when MVA infection occurred in the presence of
Fig. 3. The effect of inhibiting virus entry, but not attachment, on MVA-induced NF-κB activation and ERK2 phosphorylation. (A and B) 293T monolayers were either mock-
infected or infected with MVA or WR (MOI=10). After a 1 h absorption period at 4 °C, medium was replaced with ice-cold medium containing either mouse IgG or anti-L1R
antiserum (L1 Ab) for 15 min at 4 °C. Next, infections proceeded at 37 °C for 4 h. (C and D) 293T cells were incubated in medium either absent for or containing dynasore. At
30 min later, cells were incubated with MVA (MOI=10) in medium either containing or lacking dynasore, and infections proceeded with the drug present for 4 h. For all
ﬁgures, cells were harvested and lysed, and cytoplasmic and nuclear extracts were obtained as described in Fig. 1. (A and C) Nuclear-extracted proteins were incubated with
32P-radiolabeled oligonucleotides containing consensus NF-κB binding sites, and NF-κB activation was analyzed by using an EMSA. The NF-κB-containing band is indicated by
an asterisk. For some reactions, nuclear extracts from MVA-infected cells were incubated with an excess amount of non-radiolabeled oligonucleotides or antiserum as
described in Fig. 1. A reaction containing loading buffer only is labeled as “NC.” A super-shifted band is denoted by “+.” (B and D) Alternatively, cytoplasmically extracted
proteins from each sample were analyzed by using immunoblotting. Membranes were subsequently probed with the indicated primary antibodies. Molecular weight markers
(MW) are indicated on the left-hand side of the immunoblot. Densitometry analysis was performed to quantify the phospho-ERK2 levels in the immunoblot in panel D. The
signal from the lane containing lysates from mock-infected cells was set as a value equal to one. The signal from lanes containing lysates from MVA-infected cells was
graphically represented as a fold-increase above that observed for mock-infected cells. Values obtained from cells incubated in medium containing dynasore were also
compared to mock-infected cells.
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was necessary for NF-κB activation. At the concentration used for
this experiment, cordycepin was effective at inhibiting viral protein
expression: immunoblotted viral proteins detected with anti-
vaccinia or anti-E3 antiserum were decreased when infections
occurred in the presence of cordycepin versus its absence (Fig.
4B). Actin levels in each of the cytoplasmic lysates were
equivalent, inferring that the differences in observed viral protein
levels were not due to differences in protein levels loaded in each
sample.
To conﬁrm the necessity of viral protein expression for MVA-
induced NF-κB activation, a separate experiment, using MVAvirions pre-exposed to ultraviolet (UV) light and psoralen, was
performed. The use of these two treatments results in virions that
still bind to and enter the host cell, yet a majority of the viral
genome is not expressed or replicated (Tsung et al., 1996). In
comparison to cells infected with untreated MVA, UV/psoralen-
treated MVA no longer activated NF-κB (Fig. 5A), conﬁrming data
in Fig. 4A. When luciferase reporter assays were used as an
alternative method to indirectly measure NF-κB activation, similar
results were obtained. As shown in Fig. 5B, MVA infection of cells
induced an increase in ﬁreﬂy luciferase activity approximately 7-
fold greater than mock-infected cells, presumably reﬂecting NF-κB
activation. However, luciferase activity was decreased when cells
Fig. 4. The virus-mediated NF-κB activation state in the presence of cordycepin. 293T
cellular monolayers were incubated in medium either absent for or containing
cordycepin (40 μg/ml). At 30 min later, cells were either mock-infected or infected
with MVA (MOI=10). Where applicable, the drug was present in the medium during
the adsorption stage of infection and for the duration of the infection. At 4 h post-
infection, cells were lysed, and proteins from either the cytoplasm or the nucleus were
isolated. (A) Nuclear-extracted proteins were analyzed for NF-κB activity by EMSA, as
described in Fig. 1. The location of mobility-shifted bands containing NF-κB is indicated
by an asterisk. For some reactions, nuclear extracts from MVA-infected cells were
incubated with an excess amount of non-radiolabeled oligonucleotides or antiserum as
described in Fig. 1. In one lane, only gel loading dye was added (NC). (B) Cytoplasmic
proteins (20 μg from each sample) were analyzed by using immunoblotting, as
discussed in Fig. 1. IBs were probed with the indicated antibodies. Molecular weight
markers (MW) are indicated on the left-hand side of the ﬁgure.
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(Fig. 5B), inferring that NF-κB was inactive under these conditions.
Phospho-ERK2 was greatly decreased in cells infected with the
treated virions as compared to those incubated with unmodiﬁed
MVA (Fig. 5C), a result that was predicted. Equivalent levels of
unmodiﬁed ERK2, and the highly similar ERK1, were detected in
each sample, indicating that the differences observed for phospho-
ERK2 levels were not due to differing protein levels present in each
sample. The UV/psoralen treatment of MVA virions was effective for
decreasing viral protein synthesis. As shown in Fig. 5C, when
expressing phospho-ERK2 levels graphically, by using densitometry
to measure phospho-ERK2, it was observed that phospho-ERK2
levels were 30-fold higher in MVA-infected cells versus mock-
infected cells. In contrast, phospho-ERK2 levels were only 5-fold
above mock-infected cells when MVA virions were pre-treated with
UV and psoralen. UV/psoralen treatment of MVA dramatically
decreased the synthesis of the early E3L protein, and the L1R late
protein was no longer detected under these conditions, indicating
that the UV/psoralen treatment of virions was sufﬁcient to greatly
decrease early gene expression.
Intermediate or late gene expression, but not early gene expression, is
dispensable for MVA-induced activation of NF-κB and ERK2
Poxvirus gene expression is temporal, with early genes expressed
before viral DNA replication, and intermediate and late genes
expressed after viral DNA replication (Moss, 2007). To determine if
intermediate and late proteins were dispensable for MVA-induced NF-
κB activation, we infected 293T cells in the presence of cytosine
arabinoside (Ara C), a drug that prevents viral DNA replication, and
subsequent intermediate and late gene expression.
Under these conditions, the lack of intermediate and late protein
expression did not affect the ability of MVA to activate host cell NF-κB
at 4 h post-infection, since the nuclear translocation of NF-κB was stilldetected in nuclear extracts (Fig. 5A). Furthermore, NF-κB remained
effective as a transcriptional activator of a luciferase reporter gene in
MVA-infected cells, regardless of whether Ara C was present or absent
during infection (Fig. 5B). Not surprisingly, virus-induced ERK2
phosphorylation was unaffected by the presence of Ara C during
infection (Fig. 5C). The effectiveness of the drug in inhibiting
intermediate and late protein expression is demonstrated in Fig. 5C,
when immunoblotted lysates were probed for the presence of either
an early product (the E3L product) or a late product (the L1R product).
When comparing lysates from cells infected in Ara C-containing
versus complete medium, there was a decrease in the amount of L1R
product present, indicating a decrease in late protein synthesis. E3L
protein expressionwas not affected by the presence of Ara C, as would
be predicted.
As conﬁrmation that late viral protein expression was dispensable
for NF-κB activation, 293T cells were instead infected with MVAΔE3L,
a mutant MVA construct deleted for the early E3L ORF. As reported by
Ludwig et al. (2006), infection of 293T cells with MVAΔE3L results in
an abortive infection, in which candidate late proteins are not
produced. Under these circumstances, NF-κB remained active in
MVAΔE3L-infected cells, as detected by an EMSA (Fig. 6A). Impor-
tantly, the temporal regulation of NF-κB during MVAΔE3L infection
was similar to that observed during infectionwith MVA, implying that
the extended NF-κB activation observed during MVA infection was
solely due to early gene expression. Since ERK2 activation is required
for NF-κB activation (Gedey et al., 2006), it was not surprising to
observe that phosphorylated ERK2 was detected in extracts from
MVAΔE3L-infected cells (Fig. 6B). As would be expected, the temporal
activation of ERK2 was similar in MVAΔE3L- and MVA-infected cells.
The density of phospho-ERK2-containing bands was quantiﬁed by
using densitometry. Values for phosph-ERK2-speciﬁc signals were
computed by dividing the value of the signal obtained from lanes
containing lysates from virus-infected cells by the value of the signal
obtained from the lane containing lysates frommock-infected cells. In
this experiment, phospho-ERK2 levels were highest at 1–3 h post-
infection, with MVA infection inducing phospho-ERK2 levels 3–5-fold
above mock-infected cells. While this activation proﬁle was slightly
different than that observed for Fig. 1, we still observed ERK2
activation early during infection, and then waning at times later in
infection for both experiments. Phospho-ERK2 levels in MVAΔE3L-
infected cells were slightly lower than those of MVA-infected cells,
inducing 2–4-fold above mock-infected cells. Regardless of virus used,
phospho-ERK2 levels were similar to mock-infected cells by 4 h post-
infection.
Discussion
Modiﬁed vaccinia virus Ankara infection, unlike wild-type
vaccinia strains, activates the cellular NF-κB transcription factor
(Gedey et al., 2006; Oie and Pickup, 2001). The viral mechanism(s)
responsible for this phenotype was heretofore unknown. Using
several approaches, we identiﬁed that viral gene expression was
required for this phenotype, with the expression of the early class of
vaccinia ORFs correlating with MVA-induced NF-κB activation. Two
possibilities for this phenotype existed. First, the concomitant
expression of all early proteins was activating NF-κB via mechan-
isms such the endoplasmic reticulum overload response (EOR)
pathway. However, since MVA infection of 293T cells did not trigger
calcium release (data not shown), an event occurring during EOR
activation (Kuang et al., 2005), this possibility was unfavorable. An
alternative hypothesis is that the expression of an individual early
viral protein activates NF-κB either directly or indirectly. Experi-
mental approaches to test each of these theories are the subject of
ongoing investigations.
Recent studies have investigated the effects of MVA infection on
DC activation. Dendritic cells (DCs) are potent antigen presenting cells
Fig. 5. The effect of either Ara C treatment of cells or psoralen/UV treatment of virions on MVA-induced NF-κB activation and ERK2 phosphorylation. (A and C) Cellular
monolayers were either mock-infected or infected with MVA (MOI of 10) in medium absent for or containing 40 μg/ml Ara C. Alternatively, some MVA virions were incubated
in PBS containing psoralen (10 μg/ml) and subsequently treated with UV for 5 min before incubation with cellular monolayers (MOI=10). In all cases, at 4 h post-infection
cells were harvested, collected by centrifugation and lysed, and cytoplasmic and nuclear proteins were isolated. For (A), nuclear-extracted proteins were analyzed for NF-κB
activation by EMSAs, as described in Fig. 1. The location of mobility-shifted bands containing NF-κB is indicated by an asterisk. Some reactions contained nuclear extracts from
MVA-infected cells and either anti-NF-κB antibodies (p65 Ab), or excess amounts of non-radiolabeled oligonucleotides containing NF-κB binding sites (NF-κB) or lacking NF-κB
binding sites (AP1). A super-shifted band is indicated by a plus sign. A lane containing only loading buffer is labeled as NC. (B) Subconﬂuent 293T cell monolayers were
transfected with pRL-null and pNF-κBluc. 24 h later, cellular monolayers were either mock-infected or infected with MVA (MOI of 10) as described in (A). At 4 h post-infection
cells were harvested, collected by centrifugation and incubated in passive lysis buffer. Fireﬂy and sea pansy luciferase activities were measured, and the resultant ratios were
normalized to that value obtained using untreated, uninfected cells. (C) Cytoplasmic extracts from either mock- or virus-infected cells were analyzed for cellular and viral
proteins as described in Fig. 1. IBs were probed for either the phosphorylated (p-ERK1/2), or unphosphorylated forms of ERK1/2. Identical IBs were alternatively incubated
with anti-E3L or anti-L1R antiserum. Molecular weight (MW) markers are on the left-hand side of the immunoblot. Densitometry analysis was performed to quantify the
phospho-ERK2 levels in the immunoblot in panel C. The signal from the lane containing lysates from mock-infected cells was set as a value equal to one. The signal from lanes
containing lysates from MVA-infected cells was graphically represented as a fold-increase above that observed for mock-infected cells. Values obtained from cells incubated
with UV/psoralen-treated MVA were also compared to mock-infected cells.
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the development of adaptive immune responses (Guermonprez et al.,
2002). NF-κB activation is necessary for DC activation (Rowe et al.,
2008). One prediction from our results is that early protein synthesis
is also required for MVA-induced DC activation. This model is in
agreement with a report that UV-inactivation of MVA does not
enhance virus-induced DC activation (Samuelsson et al., 2008).
However, DC activation with UV-treated MVA has also been
documented (Drillien, Spehner, and Hanau, 2004; Waibler et al.,
2007), in contrast to our ﬁndings reported here. Additionally, MVA
activation of DCs utilizes the TLR9, an intracellular molecule known to
trigger NF-κB activation (Samuelsson et al., 2008). However, the
inhibition of TLR9-induced NF-κB activation, via over-expression of a
dominant negative MyD88 protein, did not decrease MVA-induced
NF-κB activation. Whether MVA possesses two different mechanisms
for activating NF-κB in ﬁbroblasts (early protein synthesis required,
TLR-independent) versus immune cells (early protein synthesis not
required, TLR-dependent) is the subject of future studies. Yet another
possibility is that UV irradiation of MVA is not as efﬁcient for cross-
linking the MVA genome as UV/psoralen treatment of MVA (Tsung et
al., 1996). Thus, UV-irradiated MVA virions might allow for the
transcription of viral ORFs, an event that would not occur with UV/
psoralen-treated MVA virions. Finally, these differences could be dueto varying TLR protein expression levels in ﬁbroblast versus immune
cells.
ERK2 and NF-κB activation occurred rapidly after virus infection,
raising the possibility that proteins in the mature virion may activate
NF-κB when the virus is intracellular. However, we observed two
experimental conditions in which the inhibition of viral protein
synthesis rendered NF-κB inactive in virus-infected cells (UV/
psoralen treatment of virions and incubation of cells with cordycepin).
These data support our position that nascent viral proteins are
responsible for NF-κB activation.
Curiously, NF-κB remained active in MVA-infected cells for an
extended period of time. Although MVA infection of human
monocyte-derived DCs upregulates IκBα gene expression (Guerra
et al., 2007), it is likely that virus infection in 293T cells sequesters
the auto-regulatory feedback loop for NF-κB. Whether these
patterns remain present in all ﬁbroblasts versus immune cells, and
whether this trait possesses physiological relevance, is unknown.
Equally unlikely is a late gene product prolonging NF-κB activation:
cells infected with MVAΔE3L, a deletion mutant virus that no longer
expresses intermediate or late genes in 293T cells (Ludwig et al.,
2005; Ludwig et al., 2006), have an NF-κB activation proﬁle that is
identical to that of MVA-infected cells. A current favored model for
this prolonged activation is that a viral product actively synthesized
Fig. 6. The NF-κB activation and ERK2 phosphorylation states in cells infected with MVA
viruses either lacking or containing the E3L ORF. 293T cell monolayers were either
mock-infected or infected with either MVA (MOI=10) or MVAΔE3L (MOI=10). One
hour after the absorption period, cells were incubated in fresh medium. Cellular
monolayers were incubated at 37 °C for the indicated times. Cells were lysed, and
cytoplasmic proteins and nuclear proteins were isolated. (A) Nuclear-extracted proteins
were analyzed for NF-κB nuclear translocation by using EMSAs as described in Fig.1. The
location of mobility-shifted bands containing NF-κB is indicated by an asterisk. For
some reactions, nuclear extracts from MVA-infected cells were incubated with an
excess amount of non-radiolabeled oligonucleotides or antiserum as described in Fig. 1.
A super-shifted band containing NF-κB is indicated by a plus sign. In one lane, only gel
loading dye was added (NC). (B) 20 μg cytoplasmically extracted proteins from each
sample were analyzed by immunoblotting. Membranes were probed with antibodies
recognizing either the phospho- or unmodiﬁed forms of ERK1 and ERK2. Molecular
weight (MW) markers are indicated. Densitometry analysis was performed to quantify
the phospho-ERK2 levels in the immunoblot in panel B. The signal from the lane
containing lysates from mock-infected cells was set as a value equal to one. The signal
from lanes containing lysates from MVA- or MVAΔE3L-infected cells was graphically
represented as a fold-increase above that observed for mock-infected cells.
304 S. Martin, J.L. Shisler / Virology 390 (2009) 298–306throughout infection induces this phenotype. Yet another possibility
is that an early protein that is stable throughout infection can
activate NF-κB throughout infection. Data obtained using the
MVAΔE3L virus for infection cannot rule out either of the above
possibilities.
Poxviruses are complex viruses that produce multiple immunoe-
vasion products, with many of these products important for virulence
(Moss, 2007). Data shown here indicate that vaccinia also expresses
proteins to stimulate the immune response. Why the wild-type virus
maintains multiple genes that encode proteins with opposing actions
is an important conundrum, given the traditional idea that viruses are
evolutionarily driven to minimize the number of genes they encode.This ﬁnding may indicate that temporal regulation of NF-κB activation
is more important than overall inhibition of NF-κB during vaccinia
virus pathogenesis, and leads to a new appreciation for the regulation
of this transcription factor during a poxvirus lifecycle. Notably other
viruses, such as herpes viruses, also express proteins that either
activate or inhibit NF-κB (Hiscott et al., 2006), suggesting that control
of this transcription factor by complex viruses is a common strategy
for survival and pathogenesis.
Materials and methods
Cells and viruses
The human kidney ﬁbroblast HEK293T (293T) and baby hamster
kidney (BHK-21) cell lines were obtained from the American Type
Culture Collection (ATCC). All cells were cultivated in Eagle's minimal
essential medium (EMEM) supplemented with 10% fetal calf serum
(FCS; Hyclone), referred to as complete medium. MVA is an
attenuated strain of vaccinia virus (Mayr, Hochstein-Mintzel, and
Stickl, 1975). MVAΔE3L, an MVA-based virus inwhich the E3L ORF has
been deleted (Ludwig et al., 2005), was a gift from Dr. Gerd Sutter
(Paul-Ehrlich Institut). MVAΔE3L was ampliﬁed in BHK-21 cells, while
MVAwas ampliﬁed in primary CEF cells (Charles Rivers Laboratories).
The Western Reserve (WR) strain of vaccinia virus, which was
ampliﬁed in BHK-21 cells, is considered to be a wild-type strain of
vaccinia virus.
Conditions for virus infections
Subconﬂuent 293T cell monolayers in 6-well plates were either
mock-infected or infected with either WR, MVA or MVAΔE3L at 10
plaque forming units (PFU)/cell, unless otherwise indicated. During
this absorption phase, cellular monolayers and viruses were incubated
in EMEM containing 1% FCS. After a 1 h incubation at 37 °C, virus-
containing medium was removed, and infected-cell monolayers were
incubated in fresh, complete medium. In experiments where the
activated form of ERK2 was detected, cells were instead incubated in
medium containing 1% FCS for 24 h before infection, during the
absorption stage of infection, and for the duration of infection.
Infections proceeded for indicated amounts of time, and cytoplasmic
and nuclear proteins were extracted as described below.
To allow for virus attachment to, but prevent entry into, host cells,
a previously described protocol was followed (Ramsey-Ewing and
Moss, 1998). Brieﬂy, the 1 h virus absorption (MOI=10) occurred at
4 °C, and cells were then incubated in pre-chilled medium containing
anti-L1R antibodies (1:5000 dilution; a gift from Dr. Jay Hooper,
United States ArmyMedical Research Institute for Infectious Diseases)
or antibodies not reactive to the L1 protein (murine IgG; 1:5000
dilution; Sigma Aldrich). After an additional 15 min incubation at 4 °C,
cells were incubated in prewarmed medium at 37 °C for 4 h. As an
alternative approach to prevent virus endocytosis, cells were instead
incubated in 1% FCS EMEM containing dynasore (40 mM or 80 mM;
Sigma Aldrich) for 30 min prior to infection. The drug remained
present in medium during the adsorption phase of virus infection
(MOI=10) and for the duration of infection. Cytoplasmic and nuclear
proteins were extracted as described below.
To decrease viral gene expression, MVA particles were incubated in
PBS containing 10 μg psoralen/ml (Sigma Aldrich) and subsequently
exposed to ultraviolet (UV) radiation for 5 min. These conditions,
according to a previous report, would greatly inhibit viral gene
expression (Tsung et al., 1996). Next, treated virions were incubated
with cellular monolayers for 1 h at 37 °C at an MOI of 10. Virus-
containing medium was removed and replaced with EMEM. An
alternative approach to inhibit viral protein expression was to
incubate cells with cordycepin (40 μg/ml; Sigma Aldrich) for 30 min
before infection. This drug was also present during the adsorption
305S. Martin, J.L. Shisler / Virology 390 (2009) 298–306stage of infection and for the duration of the infection. Cytoplasmic
and nuclear proteins were extracted as described below.
To inhibit intermediate and late gene expression, cells were
incubated in medium containing 40 μg/ml cytosine arabinoside (Ara
C; Sigma Aldrich) for 30 min. The drug remained present in medium
during the adsorption phase of virus infection, in which cells were
infected with 10 PFU/cell, and for the duration of infection.
Cytoplasmic and nuclear proteins were extracted as described below.
Immunoblotting of cytoplasmic-extracted proteins
For all experiments, infected cellular monolayers were dislodged
by scraping. Next, cells were collected by centrifugation (30 s at
10,000 ×g). Supernatants were removed, and cells were lysed, and
cytoplasmic proteins were collected as described previously (Gedey et
al., 2006). The protein concentration of each sample was determined
by using the BCA assay (Pierce). An equivalent amount of protein
(20 μg) from each sample was loaded into separate wells of SDS-12%
polyacrylamide gels.
Proteins were separated electrophoretically and then transferred
to a polyvinyl diﬂuoride membrane (PVDF; Millipore). Membranes
were incubated in blocking buffer (TBS containing 5% milk and 0.1%
Tween-20) for at least one hour. Next, membranes were incubated at
4 °C overnight in TBS-T (TBS containing 0.1% Tween-20 and 0.5% milk)
containing the primary antibody below. After washing membranes in
TBS-T to remove unbound primary antibodies, blots were incubated
with secondary antibody consisting of either horseradish peroxidase
(HRP)-conjugated goat anti-rabbit IgG (1:10,000; Fisher Scientiﬁc) or
HRP-conjugated goat anti-mouse IgG (1:5000; Fisher Scientiﬁc). The
antigen-antibody reactions on each immunoblot (IB) were detected
by using chemilluminescence and autoradiography. For all IBs, the
Pierce Supersignal West Pico substrate was utilized, according to the
manufacturer's directions. Primary antibodies included: rabbit anti-
phospho-ERK1/2 antiserum (1:1000; Santa Cruz Biotechnology),
which interacts with the phosphorylated form of ERK2 and the highly
similar ERK1 protein; rabbit anti-ERK1/2 antiserum (1:1000; Santa
Cruz Biotechnology), which recognizes the ERK2 and highly similar
ERK1 protein; rabbit anti-vaccinia antiserum (1:1000; Accurate
Antibody), which was raised against vaccinia virus strain Lister
particles, and contains polyclonal antiserum recognizing vaccinia
proteins that are present in a mature virions; rabbit anti-actin
antiserum (1:1000, Fisher Scientiﬁc); mouse anti-E3L antiserum
(Weaver et al., 2007) (1:1000), a gift fromDr. Stuart Isaacs (University
of Pennsylvania).
For quantiﬁcation of the phospho-ERK2 signals, X-ray ﬁlms were
digitized and analyzed by using densitometry, using the Scion Image
software (Scion Corporation). The signals were quantiﬁed by using the
“analyzing one-dimensional electrophoresis gels” program of Scion
Image, using the “GelPlot2”macro. This method was used to compare
the ratio of the band density for phospho-ERK2 only within each ﬁlm
image, where the ﬁlm exposure time to the immunoblot was identical.
A value for the phospho-ERK2-speciﬁc signal was computed by
dividing the value of signal obtained from lanes containing virus-
infected cellular lysate by the value of signal from lanes containing
lysates of mock-infected cells. In this fashion, the value obtained for
mock-infected cells was equal to one, while values of signals from
MVA-infected cells were expressed as a fold-increase of phospho-
ERK2 over uninfected cells.
Gel electromobility shift assays (EMSAs) of nuclear-extracted proteins
The method for isolating nuclear proteins from virus-infected cells
was described previously (Gedey et al., 2006). The concentration of
protein in each sample was determined by using the BCA Protein
Assay Kit (Pierce). Fivemicrograms of each extract was incubatedwith
0.35 pmol of 32P-labeled double-stranded oligonucleotides containingbinding sites for the NF-κB transcription factor (Promega) in Gel Shift
Assay System Binding buffer (Promega) as per manufacturer's
directions. Some reactions also included excess molar amounts of
non-radiolabeled oligonucleotides that either contained or lacked NF-
κB binding sites, or 1 μg monoclonal anti-p65 antiserum (Santa Cruz
Biotechnology). Following incubation, reactions were resolved elec-
trophoretically in a 6% acrylamide gel (Invitrogen) under non-
denaturing conditions, using TBE buffer. Afterward, the gels were
dried onto ﬁlter paper, exposed to a phosphorimager plate (Molecular
Devices), and images were developed and analyzed using the
ImageGauge and ImageReader programs, respectively (Fuji).
Luciferase reporter assay
A luciferase reporter assay was utilized to quantitate NF-κB
activation in cells that were infected with poxviruses, as previously
described (Shisler and Jin, 2004). For these assays, 50 ng pRL-null
(Promega) and 450 ng pNF-κBluc (Stratagene) were transfected into
subconﬂuent 293T cell monolayers in 12-well plates by using FuGene
6 transfection reagent (Roche) according to the manufacturer's
protocol. At 24 h post-transfection, 293T cell monolayers were either
mock-infected or infected with MVA (MOI=10). Alternatively, cells
were infected with MVA virions pre-treated with psoralen and UV, as
described above. To inhibit intermediate and late viral gene expres-
sion, infections instead occurred in the presence of Ara C, as described
above. In a separate experiment to detect the effect of Toll-like
receptor signaling on MVA-induced NF-κB activation, cells were co-
transfected 50 ng pRL-null, 450 ng pNF-κBluc, and 1000 ng either
pERK2DN (Gedey et al., 2006) or pMyD88DN (Nichols and Shisler,
2006). At 24 h post-transfection, cells were infected with MVA
(MOI=10) or incubated in medium containing either 10 or 20 ng IL-
1β/ml medium (Sigma). Regardless of these variations, all cells were
harvested 4 h post-infection by scraping, collected by centrifugation
(30 s at 14,000 ×g), and resuspended in passive lysis buffer
(Promega).
For all luciferase assays, the resultant lysates were assessed for
luciferase activities as described previously (Shisler and Jin, 2004). All
assays were performed in triplicate. For each experimental point,
ﬁreﬂy luciferase activity was divided by sea pansy luciferase activity to
correct for differences in transfection efﬁciencies. Resultant ratios
were averaged and normalized to the appropriate control cells (mock-
infected cells or cells co-transfected with pcDNA3.1, pNF-κBluc and
pRL-null). The value for the control cells was taken as 1. Results were
displayed as relative fold change in luciferase activity as compared to
either mock-infected cells or pcDNA3.1-transfected cells. Statistical
signiﬁcance was determined by using the Student's t-test.
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